Pharmaceutical - Cardio-vascular, Financial

Filter

Current filters:

Cardio-vascularFinancial

Popular Filters

1 to 25 of 26 results

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

17-09-2014

Privately-held Swiss pharma company Cardiorentis AG has entered into a €45 million ($58.3 million)…

Cardio-vascularCardiorentisFinancialPharmaceuticalSwitzerlandUlaritide

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Servier Canada collaborates in two research projects

Servier Canada collaborates in two research projects

17-02-2014

Two major projects in clinical research conducted by Canada’s Montreal Heart Institute (MHI) and the…

CanadaCardio-vascularFinancialNorth AmericaPharmaceuticalResearchServier

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Amarin cuts 50% of staff after negative FDA decision

23-10-2013

Amarin has announced plans to cut 50% of its staff worldwide after the recent US Food and Drug Administration…

AmarinCardio-vascularFinancialManagementNorth AmericaPharmaceuticalVascepa

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Statin drugs save health care systems money as well as saving lives, UK study shows

11-07-2013

Statins not only help save lives but are great value for money too, even in lower risk patients, according…

Cardio-vascularEuropeFinancialGenericsHealthcarePharmaceutical

Trevena and Forest Labs collaborate on TRV027 for acute heart failure

10-05-2013

US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Proposal to list AstraZeneca's Brilinta in New Zealand

26-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…

Asia-PacificAstraZenecaBrilintaCardio-vascularFinancialHealthcarePharmaceuticalPricingticagrelor

Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug

06-11-2012

Life Science Entrepreneurs, a Spanish company dedicated to the early-stage development of high-risk/very…

Ambit BiosciencesCardio-vascularFinancialLife Sciences EntrepreneursNmCOncologyPharmaceuticalquizartinibResearch

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars

26-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its…

AstraZenecaCardio-vascularFinancialLicensingManagementPharmaceuticalThe Medicines Company

Merck & Co drops development of oral vernakalant

20-03-2012

ug giant Merck & Co (NYSE: MRK) has discontinued further development of the oral formulation of vernakalant,…

BrinavessCardio-vascularCardiome PharmaFinancialMerck & CoPharmaceuticalResearchvernakalant

Lipitor and strategic collapse at Pfizer, a consultants view

05-01-2012

Now global pharma behemoth Pfizer (NYSE: PFE) spent $114 billion in 2000 for a hostile takeover of Warner-Lambert,…

Cardio-vascularFinancialLipitorMarkets & MarketingPfizerPharmaceutical

1 to 25 of 26 results

Back to top